PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer
Abstract Background Programmed cell death ligand-1 (PD-L1) and ligand-2 (PD-L2) interaction with programmed cell death protein-1 (PD-1) represent an immune-inhibiting checkpoint mediating immune evasion and is, accordingly, an important target for blockade-based immunotherapy in cancer. In non-small...
Main Authors: | Trine Vilsbøll Larsen, Dianna Hussmann, Anders Lade Nielsen |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-06-01
|
Series: | Cancer Communications |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s40880-019-0376-6 |
Similar Items
-
PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer
by: Ana Bocanegra, et al.
Published: (2019-04-01) -
New PD-L1 inhibitors in non-small cell lung cancer – impact of atezolizumab
by: Seetharamu N, et al.
Published: (2017-07-01) -
PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I Expression
by: Michal Šmahel
Published: (2017-06-01) -
Adverse Effects of Anti-PD-1/PD-L1 Therapy in Non-small Cell Lung Cancer
by: Chaoyue Su, et al.
Published: (2020-09-01) -
Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer
by: Di ZHANG, et al.
Published: (2019-06-01)